

Integrin $\beta 5$ subunit regulates hyperglycemia-induced vascular endothelial cell apoptosis through FoxO1-mediated macroautophagy

Kuze Lin¹, Sizhuang Huang¹, Side Gao¹, Jinxing Liu¹, Jiong Tang², Mengyue Yu¹

¹Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100037, China;

²Department of Cardiology, Fuwai Yunnan Cardiovascular Hospital, Kunming, Yunnan 650000, China.

Abstract

Background: Hyperglycemia frequently induces apoptosis in endothelial cells and ultimately contributes to microvascular dysfunction in patients with diabetes mellitus (DM). Previous research reported that the expression of integrins as well as their ligands was elevated in the diseased vessels of DM patients. However, the association between integrins and hyperglycemia-induced cell death is still unclear. This research was designed to investigate the role played by integrin subunit $\beta 5$ (ITGB5) in hyperglycemia-induced endothelial cell apoptosis.

Methods: We used leptin receptor knockout (Lepr-KO) (*db/db*) mice as spontaneous diabetes animal model. Selective deletion of *ITGB5* in endothelial cell was achieved by injecting vascular targeted adeno-associated virus via tail vein. Besides, we also applied small interfering RNA *in vitro* to study the mechanism of ITGB5 in regulating high glucose-induced cell apoptosis.

Results: ITGB5 and its ligand, fibronectin, were both upregulated after exposure to high glucose *in vivo* and *in vitro*. *ITGB5* knockdown alleviated hyperglycemia-induced vascular endothelial cell apoptosis and microvascular rarefaction *in vivo*. *In vitro* analysis revealed that knockdown of either *ITGB5* or *fibronectin* ameliorated high glucose-induced apoptosis in human umbilical vascular endothelial cells (HUVECs). In addition, knockdown of *ITGB5* inhibited fibronectin-induced HUVEC apoptosis, which indicated that the fibronectin-ITGB5 interaction participated in high glucose-induced endothelial cell apoptosis. By using RNA-sequencing technology and bioinformatic analysis, we identified Forkhead Box Protein O1 (FoxO1) as an important downstream target regulated by ITGB5. Moreover, we demonstrated that the excessive macroautophagy induced by high glucose can contribute to HUVEC apoptosis, which was regulated by the ITGB5-FoxO1 axis.

Conclusion: The study revealed that high glucose-induced endothelial cell apoptosis was positively regulated by ITGB5, which suggested that ITGB5 could potentially be used to predict and treat DM-related vascular complications.

Keywords: Endothelial cell apoptosis; Integrin; Autophagy; Diabetes

Introduction

Diabetes mellitus (DM) is a major metabolic disorder that is characterized by a decreased response to insulin and an increase in blood glucose levels. Epidemiologic studies have revealed a strong association between DM and microcirculation dysfunctions (e.g., diabetic retinopathy, diabetic nephropathy, and diabetic cardiomyopathy).^[1]

Several studies have indicated that DM-induced microvascular disorder is frequently accompanied by endothelial cell apoptosis and abnormal accumulation of the extracellular matrix (ECM) in the subendothelial basement membrane (BM).^[2,3] The reduction in endothelial cell number, accompanied by inappropriate elevation of the ECM in the BM, ultimately contributes to insufficient nutrient exchange and further worsens the prognosis of

DM patients.^[4,5] The ECM is a non-cellular dynamic structure that is made up of various macromolecules, such as collagens, proteoglycans, elastin, fibronectin, and other glycoproteins. The primary function of the ECM is to interact with cells and provide physical support for tissues. In addition, increasing evidence has demonstrated that the ECM also plays an important role in regulating cell viability, growth, differentiation, and metabolism.^[6] The components of the ECM are frequently remodeled by surrounding cells *via* degradation, synthesis, reassembly, and modification.^[7] Fibronectin is a multidomain glycoprotein composed of types I, II, and III repeating units. Quiescent blood vessels express less fibronectin, whereas pathological conditions (e.g., diabetes, trauma, atherosclerosis, and myocardial infarction) significantly upregulate the expression of fibronectin.^[8,9] Prior studies have

Access this article online

Quick Response Code:



Website:
www.cmj.org

DOI:
10.1097/CM9.0000000000002769

Correspondence to: Mengyue Yu, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, No. 167, North Lishi Road, Xicheng District, Beijing 100037, China
E-Mail: yumengyue@fuwaihospital.org

Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2024;137(5)

Received: 25-01-2023; Online: 27-07-2023 Edited by: Rongman Jia and Xiuyuan Hao

reported that fibronectin closely regulates the self-assembly of other ECM proteins and plays an important role in tissue remodeling during the process of DM-induced organ fibrosis.^[10,11]

Integrins, which make up a cluster of transmembrane receptors consisting of an α subunit and a β subunit, were proven to be the major receptors of ECM proteins.^[12] Pathological studies have demonstrated that the microvasculature of DM patients expresses higher levels of integrin receptors than that of control patients.^[13] The increase in integrin and ECM protein levels suggests a potential role of the integrin-ECM interaction in DM-induced microvascular dysfunction.

Previous studies of fibronectin-related integrin ligands have mainly focused on $\alpha 5\beta 1$ and $\alpha v\beta 3$, but little is known about the bioeffects of other fibronectin-related integrins. Integrin $\alpha v\beta 5$, which is abundantly expressed in human endothelial cells^[14] has been demonstrated to interact with fibronectin in prior studies.^[15,16] Through biopsies of diabetic human kidneys, it was found that the expression of $\alpha v\beta 5$ in glomeruli was elevated in correspondence with the progression of DM, which suggested that $\alpha v\beta 5$ may play an important role in DM-induced microvascular injury.^[17]

This research sought to investigate the effect of high glucose on the expression of $\alpha v\beta 5$ and fibronectin in human vascular endothelial cells. We studied the roles played by fibronectin and $\alpha v\beta 5$ in high glucose-induced endothelial cell injury and the underlying mechanisms.

Methods

Animals

The animal studies were performed in compliance with *The Guide for the Care and Use of Laboratory Animals, 8th edition (2011)*. All the experimental procedures were approved by the Experimental Animals Ethics Committee of Fuwai Hospital (No. FW-2021-0004). Male leptin receptor-knockout (*db/db*) mice (6 weeks old, C57Bl/6J) and non-diabetic *db/m* mice were obtained from Cyagen Biosciences (Suzhou, China) and fed normal chow. To selectively delete integrin subunit $\beta 5$ (*ITGB5*) from vascular endothelial cells, vascular targeted adeno-associated virus (AAV-Vec, Hanbio Biotechnology Co., Ltd, Shanghai, China) with a specific endothelial cell promoter (*TEK* receptor tyrosine kinase, *TIE2*) expressing *ITGB5* short hairpin ribonucleic acid (shRNA, miR-30 based) was administered to the mice via tail vein injection (10^{10} PFU/mice) after one week of adaptation. After 4 weeks of injection, all the mice were sacrificed under deep anesthesia (induced by intraperitoneal injection of sodium pentobarbital at 50 mg/kg), and their plasma and heart were collected for further analysis.

Isolation of endothelial cells from mouse myocardial tissue was performed by using anti-mouse-CD31 microbeads (Miltenyi Biotec GmbH, San Diego, California, USA) as previously described.^[18] Briefly, mouse myocardial tissue was washed with cold phosphate buffer solu-

tion (PBS) for 3 times and enzymatically dissociated in endothelial cell culture medium (ECCM, Sciencell, Cat. No. 1001, San Diego, California, USA) that contained collagenase/dispase/0.1% trypsin/1.0 mmol/L ethylene diamine tetraacetic acid for 30 min at 37°C. The cells were centrifuged for 5 min at 400 \times g and 4°C. The cell pellets were resuspended in ECCM, passed through a Falcon cell strainer (BD, Lake Franklin, New Jersey, USA) with a pore size of 70 μ m, and collected using a 50 mL centrifuge tube. Thereafter, the cells were resuspended in ECCM and sorted with anti-CD31 magnetic beads. CD31⁺ cells were considered endothelial cells.

Cell culture and treatment

This study complied with the ethical guidelines of the 1975 *Declaration of Helsinki*, and was approved by the Ethics Committee of Fuwai Hospital (No. IRB2012-BG-006). All the participants were informed and signed consent form at the time of enrollment. The isolation and identification of human umbilical vascular endothelial cells (HUVECs) were performed in a manner that was consistent with the previously described instructions.^[19] HUVECs were maintained in ECCM (manufactured by Sciencell, Cat. No. 1001, San Diego, California, USA) supplemented with 5% fetal bovine serum (FBS), 1% endothelial cell growth supplement (ECGS, manufactured by Sciencell, Cat. No. 1052), and 1% penicillin/streptomycin solution at 37°C in a humid atmosphere with 5% CO₂. HUVECs were used in the experimental analyses within 4 passages. High-glucose ECCM and normal-glucose ECCM were made by adding D-(+)-glucose (Sigma Aldrich, G7021, Wisconsin, USA) and glucose-free ECCM (Sciencell), respectively.

Small interfering RNA (siRNA) purchased from GenePharma (Suzhou, China) was used for the transient knock-down of target genes. The nucleotide sequences of siRNAs are listed in Supplementary Table 1, <http://links.lww.com/CM9/B622>. Lipofectamine RNAiMAX transfection reagent (Invitrogen, California, Carlsbad, USA) was used, and the transfection experiment was performed consistent with the instructions provided by the manufacturer. HUVECs were transfected with siRNAs in Opti-MEMTM (Gibco, Carlsbad, California, USA) for 6 h. After transfection, the medium was replaced by normal culture medium (ECCM supplemented with 5% FBS and 1% ECGS), and the cells were incubated for another 12 h. The interference efficiency was determined by Western blotting analysis.

Cell apoptosis assay

An *in situ* cell death detection kit (terminal deoxynucleotidyl transferase mediated dUTP nick-end labeling [TUNEL] assay kit, Roche Applied Science, 11767291910, Basel, Switzerland) was used to assess cell apoptosis *in vivo* and *in vitro*. Apoptotic cells in the sections of mouse myocardial tissues were stained according to the manufacturer's instructions, and slides were counter-stained for endothelial cells using an antibody against CD31. HUVECs were grown in confocal dishes (NEST, Wuxi, China) before TUNEL staining. The experiment

was carried out according to the manufacturer's instructions. 4', 6-diamidino-2-phenylindole (DAPI, Abcam, ab104139, Cambridge, UK) was used to stain the cell nuclei. Images were captured by LEICA TCS SP5 MP (Leica, Wetzlar, Germany).

Protein extraction and Western blotting

After being isolated from mouse myocardial tissues, endothelial cells (CD31⁺) were added to lysis buffer (radio-immunoprecipitation assay [RIPA] buffer containing 1 mmol/L phenylmethanesulfonyl fluoride [PMSF]) to extract the total proteins. The protein concentration of each sample was quantified and equilibrated before Western blotting.

Cells were rinsed twice with cold PBS and collected with a scraper. RIPA buffer (Thermo Fisher, 89901, Waltham Massachusetts, USA) containing 1 mmol/L PMSF (Solarbio, P0100, Beijing, China) was used to extract the total proteins from cells. A protein phosphatase inhibitor (Solarbio, P1260) was added to RIPA buffer when extracting phosphorylated proteins. A nuclear protein extraction kit (Beyotime, P0027, Shanghai, China) was used to extract nuclear proteins from cells, and the experiment was performed according to the manufacturer's instructions. The protein concentration of each sample was equilibrated before the immunoblotting experiments. Antibodies were purchased from Abcam and Cell Signaling Technology (Boston, Massachusetts, USA), and their category number is shown in Supplementary Table 2 [<http://links.lww.com/CM9/B622>]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize the expression of the target protein in each sample. Secondary antibodies were purchased from LI-COR Bioscience (California, San Diego, USA).

Immunofluorescence assay and colocalization analysis

Mouse myocardial samples were collected and fixed for immunofluorescence analysis. To assess the capillary density in the myocardium, the samples were sliced into 8- μ m frozen sections for immunofluorescence staining of CD31.

Cells were grown in confocal dishes (NEST). After rinsing with cold PBS, the cells were fixed with 4% paraformaldehyde for 15 min and incubated with PBS containing 0.3% Triton (Solarbio) for 15 min to permeabilize the membrane. Subsequently, the cells were rinsed twice and incubated with primary antibody overnight. On the next day, the cells were rinsed and incubated with secondary antibody for 45 min. Mounting medium with DAPI (Abcam) was added and incubated with cells for 5 min before analysis. Images were captured by a LEICA TCS SP5 MP, and fluorescence intensity was quantified by ImageJ software (Bethesda, Maryland, USA). The antibodies used for analysis are listed in Supplementary Table 2 [<http://links.lww.com/CM9/B622>].

We used two different methods to assess the spatial colocalization of two proteins. First, we set the proper area

(area of interest, AOI) in pictures where both proteins were well labeled. We used Image-Pro Plus 6.0 (Media Cybernetics Inc, California, USA) to evaluate the Pearson correlation values and overlap coefficient of two proteins in AOI. If Pearson correlation values and overlap coefficients ranged from 0.5 to 1.0, the two proteins were considered to be significantly co-localized.^[20] Additionally, we also used one-dimensional analysis to assess the colocalization of two proteins, which has been proven to be a practical method in previous studies.^[21]

RNA extraction and real-time quantitative polymerase chain reaction (RT-qPCR) analysis

Cells were rinsed, and total RNA was extracted by using TRIzol Reagent (Invitrogen). TransScript One-Step gDNA Removal and cDNA Synthesis SuperMix (Transgen Biotech, Beijing, China) was used to conduct reverse transcription, and real-time PCR was performed by applying Top Green qPCR Supermix (Transgen Biotech). Experiments were performed according to the manufacturer's instructions. We used GAPDH to standardize the expression of target genes, and the primer sequences are shown in Supplementary Table 3, <http://links.lww.com/CM9/B622>. We quantified the expression of target genes by calculating $2^{-\Delta\Delta C_t}$ values.

Lentiviral transfection process

After isolation from tissues, HUVECs were incubated in normal medium for 48 h before transfection with lentivirus. To detect the autophagic flux in HUVECs, we used green fluorescent protein (GFP)-monomeric red fluorescent protein (mRFP)-microtubule associated protein light chain 3 (LC3) lentivirus (Hanbio Biotechnology Co, Ltd) to label autophagosomes and monitor their formation and degradation. To establish a stable FoxO1-overexpressing HUVEC cell line, we used *flag-PURO-FoxO1* lentivirus (Hanbio Biotechnology Co, Ltd) to infect HUVECs at a multiplicity of infection (MOI) of 30 (with 4 μ g/mL polybrene) and selected stable transfectants by adding puromycin at a concentration of 2 μ g/mL. Immunoblotting of the Flag tag was used to validate the successful transfection of FoxO1.

RNA sequencing (RNA-seq) analysis

RNA-seq and analysis were performed by Annoroad Gene Technology Co. (Beijing, China), and the Illumina platform (San Diego, California, USA) was used. The concentration and quality of all the samples were determined before the analysis. Individual cDNA libraries were constructed by using RNA samples. Cluster generation and sequencing were performed on the NovaSeq 6000 S4 platform using the NovaSeq 6000 S4 Reagent kit V1.5 (Illumina, San Diego). The false discovery rate (FDR) was calculated, and differential expression of genes was determined by using DESeq2 algorithms.^[22] The *P*-value of each gene was calculated and adjusted by Benjamini and Hochberg's approach for controlling the FDR (*q* value). Genes with *q* \leq 0.05 and \log_2 fold change \geq 1 were defined as differentially expressed genes (DEGs).

The rich ratio of pathways was quantified by using Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The raw RNA-seq data were uploaded to the Sequence Read Archive (SRA) database under accession number PRJNA931645.

Statistical analysis

The results are presented as the mean \pm standard deviation (SD) for continuous data. We performed the Kolmogorov–Smirnov test to determine whether the data conformed to a normal distribution. The Kruskal–Wallis test was used to determine if means across groups were significantly different before reporting analysis of variance (ANOVA)-associated *post hoc* test results. One-way ANOVA followed by Bonferroni multiple comparisons *post hoc* test was performed to assess the significance of the deviation when three or more groups were involved. For data that did not follow a normal distribution, non-parametric tests (Wilcoxon rank test) were used. The statistical methods used in graphs are described in the Supplementary Table 4 [<http://links.lww.com/CM9/B622>]. All the data were analyzed by GraphPad Prism 7 (San Diego, California, USA). *P*-values <0.05 were considered statistically significant. Representative images were selected as those that showed values close to the means of the results obtained from all analyzed samples.

Results

Hyperglycemia promoted endothelial apoptosis and reduced capillary density in the myocardium of diabetic mice, whereas knockdown of *ITGB5* attenuated these effects

Compared with *db/m* mice, fasting blood glucose levels significantly increased in *db/db* mice. Selective knockdown of *ITGB5* in vascular endothelial cells did not have a significant effect on fasting blood levels in *db/db* mice [Table 1]. Immunoblotting analysis of vascular endothelial cells isolated from the myocardium revealed that the expression of fibronectin, integrin αv (ITGAV), and *ITGB5* was increased in the vascular endothelium of diabetic mice [Figures 1A–D]. Protein expression analysis also indicated that the expression of *ITGB5* was successfully knocked down by using an AAV-Vec-based *ITGB5* shRNA delivery strategy [Figures 1A,D]. In addition,

macroautophagy (hereafter referred to as autophagy) activity in endothelial cells was observed to be elevated under hyperglycemic conditions, whereas knockdown of *ITGB5* significantly attenuated autophagy [Figures 1A, E]. These observations suggested that integrin may play a role in regulating hyperglycemia-associated endothelial injury.

We further investigated the effects of hyperglycemia on capillary density and endothelial cell apoptosis in the myocardium of diabetic mice. Endothelial cells were labeled with a CD31 antibody and dyed red [Figure 1F]. Immunofluorescence analysis of myocardial tissue indicated that capillary density was markedly decreased in diabetic mice; however, knocking down *ITGB5* expression in endothelial cells partially rescued hyperglycemia-induced capillary rarefaction [Figures 1F,G]. The nuclei of apoptotic cells were dyed green using a TUNEL assay kit [Figure 1F]. Apoptotic endothelial cells were detected by overlapping the green signal and red signal [Figure 1F]. The results revealed that hyperglycemia promoted endothelial cell apoptosis, whereas knockdown of *ITGB5* alleviated apoptosis in endothelial cells [Figures 1F,H]. By using an animal model of diabetes, we demonstrated that *ITGB5* played an important role in mediating hyperglycemia-induced endothelial injury.

High glucose induced the overexpression of integrin $\alpha v\beta 5$ and fibronectin in HUVECs

To explore the effects of high glucose on endothelial cells, we incubated HUVECs under normal glucose (5 mmol/L) or high glucose (33 mmol/L) conditions for different lengths of time. Total RNA and protein were extracted from cells and subjected to RT-qPCR [Supplementary Figures 1A–C, <http://links.lww.com/CM9/B622>] and immunoblotting analysis [Supplementary Figure 1D, <http://links.lww.com/CM9/B622>]. The results indicated that after stimulation with high glucose for 6 h, 24 h, and 48 h, the expression of *fibronectin* and *ITGAV* was significantly elevated [Supplementary Figures 1A, B, E, F, <http://links.lww.com/CM9/B622>]. However, in comparison with the control group, the expression of *ITGB5* in the high glucose-treated group only started to increase after 24 h of stimulation [Supplementary Figures 1C, D, G, <http://links.lww.com/CM9/B622>]. In addition, to investigate the expression level of the $\alpha v\beta 5$ heterodimer

Table 1: Characteristics of *db/m* mice, *db/db* mice and *db/db* mice with *ITGB5* shRNA injection (*db/db*+*ITGB5* shRNA).

Characteristics	<i>db/m</i>	<i>db/db</i>	<i>db/db</i> + <i>ITGB5</i> shRNA
<i>n</i>	11	11	11
Male (%)	100	100	100
Age (weeks)	12	12	12
Body weight (g)	24.1 \pm 0.7	37.6 \pm 0.6*	36.6 \pm 0.6*
Fasting blood glucose (mg/dL)	173.6 \pm 5.0	454.1 \pm 16.3*	448.5 \pm 15.1*

**P* <0.0001 vs. *db/m*. Data are expressed as *n* or mean \pm standard deviation. Baseline characteristics of experimental animals were recorded. The 8-week gene-modified mice was subjected to AAV-based *ITGB5* shRNA delivery through tail vein injection. Four weeks after injection, their blood samples were collected and analyzed. AAV: Adeno-associated virus; *ITGB5*: Integrin subunit $\beta 5$; shRNA: Short hairpin ribonucleic acid.




Figure 1: Assessment of diabetic mice. Some of eight-week gene-modified mice were subjected to AAV-based *ITGB5* shRNA delivery through tail vein injection. Four weeks after injection, myocardial samples were collected and analyzed. (A) Mouse cardiac vascular endothelial cells were isolated from the myocardium and subjected to Western blotting analysis. (B–E) Relative gray values were used to indicate the expression intensity of target proteins ($n = 4$ /group). (F) Mouse myocardial samples were stained with immunofluorescent antibodies to determine the expression of the target protein ($n = 7$ /group). CD31 (the marker of endothelial cells) was stained red. Apoptotic cells were detected by TUNEL assay (green). The nuclei of the cells were stained with DAPI (blue). The apoptotic endothelial cells were visualized by overlapping the red signal, green signal, and blue signal (marked by arrows). (G) The capillary density of the myocardium was determined by calculating the number of capillaries per square millimeter (NA/mm^2). (H) The degree of endothelial cell apoptosis is expressed as the percentage of TUNEL-positive endothelial cells. In the graphs, the data are expressed as the mean \pm standard deviation. * $P < 0.05$, † $P < 0.001$, ‡ $P < 0.01$. AAV: Adeno-associated virus; DAPI: 4', 6-diamidino-2-phenylindole; ECs: Endothelial cells; FBN: Fibronectin; ITGAV: Integrin subunit α ; ITGB5: Integrin subunit β ; LC3: Microtubule associated protein light chain 3; n.s: Not significant; shRNA: Short hairpin ribonucleic acid; TUNEL: Terminal deoxynucleotidyl transferase mediated dUTP nick-end labeling.

(consisting of ITGAV and ITGB5) and fibronectin, we performed immunofluorescence microscopy [Supplementary Figure 1H, <http://links.lww.com/CM9/B622>]. The

results we obtained from immunofluorescence analysis corresponded with those from RT-qPCR and immunoblotting, which indicated that expression of fibronectin

started to rise after 6 hours of incubation [Supplementary Figure 1I, <http://links.lww.com/CM9/B622>], while $\alpha v \beta 5$ started to increase after 24 h of incubation [Supplementary Figure 1J, <http://links.lww.com/CM9/B622>].

Previous studies have demonstrated that fibronectin can bind to integrin $\alpha v \beta 5$. To determine whether fibronectin colocalized with $\alpha v \beta 5$ in HUVECs under the experimental conditions, we performed immunofluorescence analysis. We set the proper area for colocalization analysis and quantified the Pearson correlation values ($R_r = 0.720453$) and overlap coefficient ($R = 0.803709$), which suggested that fibronectin significantly colocalized with $\alpha v \beta 5$ in HUVECs [Supplementary Figure 1K, <http://links.lww.com/CM9/B622>]. One-dimensional analysis of the representative area also indicated obvious colocalization of these two proteins [Supplementary Figure 1L, <http://links.lww.com/CM9/B622>].

High glucose-induced overexpression of fibronectin promoted apoptosis in HUVECs through *ITGB5*

To validate the role played by the fibronectin- $\alpha v \beta 5$ interaction in high glucose-induced cell apoptosis, we assessed the expression of apoptosis-related proteins. The results showed that after incubation under high glucose conditions for 24 h, the expression level of cleaved caspase-3, which is an initiator of the apoptotic pathway, was significantly elevated [Figures 2A, B]. Of note, the trend in cleaved caspase-3 expression was similar to that of the $\alpha v \beta 5$ heterodimer and *ITGB5*, which suggested underlying associations between these proteins. After knocking down the expression of fibronectin, the elevation of cleaved caspase-3 induced by high glucose was significantly inhibited [Figures 2A, B]. These results indicated that the fibronectin- $\alpha v \beta 5$ axis could play an important role in high glucose-induced endothelial cell apoptosis.

To determine which subunit was indispensable in triggering cell apoptosis, we used gene intervention technology to knock down the *ITGAV* or *ITGB5*. Immunoblotting analysis revealed that knockdown of the *ITGB5* reduced the high glucose-induced or fibronectin-induced elevation of proapoptotic proteins (cleaved caspase-3 and bax) and increased the expression of an anti-apoptotic protein (bcl-2) [Figures 2C–J]. However, knockdown of the *ITGAV* did not significantly inhibit cell apoptosis under identical conditions [Figures 2C–J]. In addition to protein expression analysis, we also used TUNEL staining to investigate apoptosis at the cellular level. The results were consistent with those from immunoblotting analysis [Figures 2K–N]. Combined with the protein expression and TUNEL staining results, we discovered that expression of the *ITGB5* is critical for both high glucose-induced and fibronectin-induced HUVEC apoptosis.

ITGB5 knockdown alleviated autophagy induced by high glucose and fibronectin

It has been reported that autophagy, which is a cellular mechanism for combating stress-induced damage, plays

a vital role in high glucose-induced cell apoptosis.^[22] Therefore, we further investigated the effects of *ITGB5* on cell autophagy activity. Chloroquine (CQ) was used to block autophagosome degradation so that we could monitor the intensity of the autophagic flux. Through immunoblotting analysis, we found that both high glucose and fibronectin stimulated the expression of beclin1 (the initiator of autophagy) and degradation of LC3 II [Supplementary Figure 2, <http://links.lww.com/CM9/B622>]. However, we also discovered that the expression of Atg7 (which mainly regulates the maturation of autophagosomes) remained unchanged [Supplementary Figure 2, <http://links.lww.com/CM9/B622>]. The results above suggested that both high glucose and fibronectin can promote the formation of autophagosomes in endothelial cells, but the ability of these cells to process autophagosomes was not elevated accordingly. After knocking down the expression of *ITGB5*, the level of beclin1 was downregulated, and degradation of LC3 II was restricted, while the expression of Atg7 was unaffected [Supplementary Figure 2, <http://links.lww.com/CM9/B622>].

In addition, we also constructed an GFP-mRFP-LC3-expressing cell line to monitor the transition of autophagosomes to autolysosomes. The early-stage autophagosome was labeled by both mRFP and GFP. After being fused with lysosomes, the autophagosome changed into an autolysosome, and GFP was degraded, which made it only labeled by mRFP. The fluorescence microscopy results indicated that autophagosome transition was active in both the high glucose-treated and fibronectin-treated groups [Supplementary Figure 2, <http://links.lww.com/CM9/B622>]. After knockdown of the *ITGB5*, the autophagic flux was significantly inhibited under both conditions [Supplementary Figure 2, <http://links.lww.com/CM9/B622>]. The results further indicated that fibronectin- $\beta 5$ was involved in autophagy regulation under high glucose stimulation.

FoxO1 was a downstream target regulated by integrin $\beta 5$

To identify the downstream signaling pathway regulated by integrin $\beta 5$, we conducted RNA-seq analysis and further validated the results by immunoblotting experiments. According to our hypothesis, high glucose elevated the expression of fibronectin in HUVECs, which then stimulated cell apoptosis via integrin $\beta 5$. Therefore, we designed two cell models in which apoptosis was activated by high glucose or fibronectin. After knocking down *ITGB5* in both models, we used RNA-seq technology to determine the gene expression profiles of the samples. KEGG pathway analysis was used to identify differentially regulated pathways in the *ITGB5*-knockdown groups. Sample clustering analysis showed good intragroup consistency [Supplementary Figure 3, <http://links.lww.com/CM9/B622>]. The number of differentially regulated genes is shown in Supplementary Figure 4 [<http://links.lww.com/CM9/B622>]. FDR was evaluated and used to assess the significance of differences in pathway enrichment between *ITGB5*-knockdown groups and control groups. The pathways with FDR less than 0.05 were considered to be significant [Supplementary Figure 5, <http://links.lww.com/CM9/B622>]. We screened 10




Figure 2: High glucose-induced overexpression of fibronectin promoted apoptosis in HUVECs through ITGB5. (A) After transfection with negative control siRNA or fibronectin siRNA, HUVECs were incubated in high-glucose ECCM (containing 0.2% FBS and 33 mmol/L glucose) or normal-glucose ECCM (containing 0.2% FBS and 5 mmol/L glucose) for 6 h, 24 h, and 48 h. Protein was extracted from each sample and subjected to Western blotting analysis ($n = 3/\text{group}$). (B) Relative gray values were used to indicate the expression intensity of target proteins. (C) In control group, HUVECs were transfected with negative siRNA and then incubated in high-glucose ECCM for 24 h. And other HUVECs were transfected with negative control siRNA, *ITGB5* siRNA, or *ITGAV* siRNA and then incubated in high-glucose ECCM for 24 h. Protein from each sample was extracted and subjected to Western blotting analysis ($n = 4/\text{group}$). (D–F) Relative gray values were used to indicate the expression intensity of target proteins. (G) In control group, HUVECs were transfected with negative siRNA and then incubated in vehicle-containing ECCM (5 $\mu\text{g}/\text{mL}$ fibronectin, 0.1% FBS, 5 mmol/L glucose) for 6 h. And other HUVECs were transfected with negative control siRNA, *ITGB5* siRNA, or *ITGAV* siRNA and then incubated in fibronectin-containing ECCM (5 $\mu\text{g}/\text{mL}$ fibronectin, 0.1% FBS, 5 mmol/L glucose) for 6 h. Protein was extracted from each sample and subjected to Western blotting analysis ($n = 4/\text{group}$). (H–J) Relative gray values were used to indicate the expression intensity of target proteins. (K) In control group, HUVECs were transfected with negative siRNA and then incubated in normal-glucose ECCM for 24 h. And other HUVECs were transfected with negative control siRNA, *ITGB5* siRNA, or *ITGAV* siRNA and then incubated in high-glucose ECCM for 24 h. Samples were subjected to TUNEL staining ($n = 6/\text{group}$, TUNEL-positive nuclei were marked by arrows). (L) The apoptosis rate was quantified by calculating the percentage of TUNEL-positive cells. (M) In control group, HUVECs were transfected with negative siRNA and then incubated in vehicle-containing ECCM for 6 h. And other HUVECs were transfected with negative control siRNA, *ITGB5* siRNA, or *ITGAV* siRNA and then incubated in fibronectin-containing ECCM (5 $\mu\text{g}/\text{mL}$ fibronectin, 0.1% FBS, 5 mmol/L glucose) for 6 h. Samples were subjected to TUNEL staining ($n = 6/\text{group}$, TUNEL-positive nuclei are marked by arrows). (N) The apoptosis rate was quantified by calculating the percentage of TUNEL-positive cells. In the graphs, the data are expressed as the mean \pm standard deviation. * $P < 0.01$, † $P < 0.001$. BAX: B-cell lymphoma-2 associated X; BCL-2: B-cell lymphoma-2; DAPI: 4',6-diamidino-2-phenylindole; ECCM: Endothelial cell culture medium; FBN: Fibronectin; FBS: Fetal bovine serum; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; HG: High-glucose medium; HUVECs: Human umbilical vascular endothelial cells; ITGAV: Integrin subunit αv ; ITGB5: Integrin subunit β5 ; KD: Knockdown; NC: Negative control siRNA; NG: Normal-glucose medium; n.s.: Not significant; siRNA: Small interfering RNA. TUNEL: Terminal deoxynucleotidyl transferase mediated dUTP nick-end labeling.

pathways with the most significant differences according to the FDR ranking, and we arranged them through their rich ratio. The advanced glycation end products (AGE)-receptor of advanced glycation end product (RAGE) signaling pathway showed a significant difference after knocking down the expression of the *ITGB5* in both models [Supplementary Figure 6, <http://links.lww.com/CM9/B622>]. Then, we analyzed the expression levels of genes regulated by the AGE-RAGE pathway. The results indicated that after knocking down the expression of *ITGB5* in both models, AGE-RAGE pathway activity was attenuated [Supplementary Figure 6, <http://links.lww.com/CM9/B622>]. Furthermore, we selected 10 genes regulated by the AGE-RAGE pathway and performed RT-qPCR analysis to validate their expression levels. The results also demonstrated that the knockdown of *ITGB5* mark-

edly reduced the activity of the AGE-RAGE pathway [Supplementary Figure 6, <http://links.lww.com/CM9/B622>]. On the basis of the RNA-seq and RT-qPCR results, it was suggested that *ITGB5* was a potential regulator of the AGE-RAGE pathway. Previous research indicated that FoxO1 is an important transcription factor that is regulated by the AGE-RAGE pathway, which controls the autophagic flux and cell apoptosis under high-glucose conditions.^[23]

To further validate the RNA-seq results, we subsequently designed experiments to examine the effects of *ITGB5* on the functions of FoxO1. Immunoblotting analysis indicated that high glucose and fibronectin both induced FoxO1 expression and nuclear translocation [Supplementary Figure 7, <http://links.lww.com/CM9/B622>].

However, after knocking down *ITGB5*, these bioeffects were significantly ablated [Supplementary Figure 7, <http://links.lww.com/CM9/B622>]. Immunofluorescence microscopy showed that FoxO1 nuclear translocation was markedly activated after stimulation with high glucose or fibronectin, and the knockdown of *ITGB5* strongly ameliorated these effects [Supplementary Figure 7, <http://links.lww.com/CM9/B622>].

FoxO1 regulated the excessive autophagy induced by high glucose and fibronectin, which contributed to HUVEC apoptosis

We further investigated the role of autophagy in high glucose-induced and fibronectin-induced HUVEC apoptosis. On the basis of the autophagy-related protein assay that we conducted, beclin1 was correlated with the elevation of autophagy under experimental conditions. In addition, we also sought to validate the association between FoxO1 and cell apoptosis induced by high glucose and fibronectin. The knockdown of either *FoxO1* or *beclin1* markedly inhibited the expression of pro-apoptotic proteins (cleaved caspase-3 and bax) and elevated anti-apoptotic protein (bcl2) [Supplementary Figure 8, <http://links.lww.com/CM9/B622>]. The TUNEL analysis also indicated that both *FoxO1* knockdown and *beclin1* knockdown attenuated cell death under the provided conditions [Supplementary Figure 8, <http://links.lww.com/CM9/B622>].

The above results indicated that beclin1-related autophagy played a deleterious role in the apoptosis elicited by high glucose or fibronectin. In addition, the knockdown of *FoxO1* significantly reversed the beclin1 overexpression and autophagy that were induced by high glucose or fibronectin [Supplementary Figure 9, <http://links.lww.com/CM9/B622>], which indicated that beclin-1-related autophagy was regulated by FoxO1.

Overexpression of FoxO1 reversed the effects of *ITGB5* knockdown

To determine whether FoxO1 was a downstream target by which *ITGB5* regulates cell apoptosis, we constructed a FoxO1-overexpressing cell line. The immunoblotting of the Flag tag indicated the successful transfection of FoxO1 [Figure 3]. The detection of cleaved caspase-3 revealed that overexpression of FoxO1 in HUVECs significantly reduced the anti-apoptotic effects of *ITGB5* knockdown [Figure 3]. In addition, after knocking down *ITGB5*, the apoptotic rate in the empty vector-transfected group was reduced [Figure 3], while FoxO1-overexpressing HUVECs did not exhibit a significant difference [Figure 3]. We also investigated the effects of FoxO1 overexpression on *ITGB5*-mediated autophagy. The immunoblotting results showed that the empty vector did not affect *ITGB5* knockdown-induced reduc-




Figure 3: The overexpression of FoxO1 in HUVECs reduced the protective effects of *ITGB5* knockdown under high glucose conditions. FoxO1-overexpressing HUVECs and empty vector-infected HUVECs were transfected with negative control siRNA or *ITGB5* siRNA, and both were stimulated with high-glucose medium for 24 h. (A) Western blotting analysis was used to measure the expression of target proteins. (B, C) Relative gray values were used to indicate the expression intensity of target proteins ($n = 4$ /group). (D) TUNEL analysis was used to analyze cell death. The nuclei of dead cells were stained green ($n = 6$ /group, TUNEL-positive nuclei are marked by arrows). (E) The apoptosis rate was quantified by calculating the percentage of TUNEL-positive cells ($n = 6$ /group). (F) TUNEL analysis was used to analyze cell death. The nuclei of dead cells were stained green ($n = 6$ /group, TUNEL-positive nuclei are marked by arrows). (G) The apoptosis rate was quantified by calculating the percentage of TUNEL-positive cells ($n = 6$ /group). In the graphs, the data are expressed as the mean \pm standard deviation. * $P < 0.001$. DAPI: 4', 6-diamidino-2-phenylindole; FoxO1: Forkhead Box Protein O1; HG: High-glucose medium; HUVECs: Human umbilical vascular endothelial cells; *ITGB5*: Integrin subunit $\beta 5$; KD: Knockdown; n. s.: Not significant; NC: Negative control siRNA; NG: Normal-glucose medium; siRNA: Small interfering RNA; TUNEL: Terminal deoxynucleotidyl transferase mediated dUTP nick-end labeling.

tion in autophagy [Figure 4]. However, the overexpression of FoxO1 markedly reversed the decrease in autophagy

induced by *ITGB5* knockdown [Figure 4]. The graphical abstract of this research was shown in Figure 4G.




Figure 4: The overexpression of FoxO1 reversed the anti-autophagy effects of *ITGB5* knockdown under high glucose conditions. FoxO1-overexpressing HUVECs and empty vector-infected HUVECs were transfected with negative control siRNA or *ITGB5* siRNA and then stimulated with high-glucose medium for 26 h. In several groups, CQ (50 μmol/L) was added to the medium in the last 2 h of incubation. (A) Western blotting was used to measure the expression of target proteins in samples. (B,C) Relative gray values were used to indicate the expression intensity of target proteins ($n = 4$ /group). (D) Western blotting was used to measure the expression of target proteins in samples. (E,F) Relative gray values were used to indicate the expression intensity of target proteins ($n = 4$ /group). Δ LC3 II represents LC3 II degradation, which positively correlates with the autophagy flux. (G) The graph shows that the *ITGB5*–FoxO1 axis regulated excessive autophagy induced by high glucose and reduced autophagy-related cell apoptosis in HUVECs. In the graphs, the data are expressed as the mean \pm standard deviation. * $P < 0.001$, † $P < 0.01$. CQ: Chloroquine; FoxO1: Forkhead Box Protein O1; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; HG: High-glucose medium; HUVECs: Human umbilical vascular endothelial cells; *ITGB5*: Integrin subunit $\beta 5$; KD: Knockdown; LC3: Microtubule associated protein light chain 3; NC: Negative control siRNA; NG: Normal-glucose medium; n.s.: Not significant; siRNA: Small interfering RNA.

Discussion

Our research indicated that ITGB5 played an important role in regulating hyperglycemia-induced endothelial cell apoptosis. Animal research revealed that after stimulation with high glucose, endothelial cell apoptosis was elevated and capillary density was significantly reduced in diabetic mice. After knocking down the expression of *ITGB5* in endothelial cells, these effects were attenuated. *In vitro* analysis indicated that the $\alpha v\beta 5$ heterodimer (consisting of ITGAV and ITGB5) as well as its ligand, fibronectin, was upregulated by high glucose. The knockdown of *fibronectin* significantly attenuated high glucose-induced apoptosis, while the addition of fibronectin elevated endothelial cell apoptosis, which suggested that fibronectin was a positive regulator of apoptosis under high-glucose conditions. We also demonstrated that knockdown of the *ITGB5*, but not the *ITGAV*, can alleviate the cell apoptosis induced by high glucose and fibronectin. This result indicated that the *ITGB5* played a more important role than the *ITGAV* in high glucose-induced and fibronectin-mediated endothelial cell apoptosis. In addition, we further confirmed that *ITGB5* modulated FoxO1 expression and nuclear translocation, which subsequently regulated the autophagy-related apoptosis induced by high glucose. After FoxO1 was overexpressed in endothelial cells, the effects elicited by *ITGB5* knockdown were significantly diminished.

Dysfunction of the vascular endothelium is the hallmark of the cardiovascular complications induced by diabetes. In patients with type 2 diabetes mellitus (T2DM), the macrovascular system (consisting of elastic arteries, muscular conduit arteries, and muscular resistance arteries) begins to exhibit pathological changes in the prediabetic stages, which are mainly characterized by the proliferation of smooth cells and improper deposition of matrix.^[24] On the other hand, the microcirculation system is composed of capillaries, which have no media structure and are mainly made by the endothelium and regulated by endothelial functions. Previous studies revealed a solid association between hyperglycemia and endothelial dysfunction, which can contribute to damage to the microcirculation system.^[25] Through the analysis of myocardium samples from DM patients and diabetic pigs, Hinkel *et al*^[26] demonstrated that diabetes markedly induced capillary rarefaction and pericyte loss. These pathological changes significantly affected organ functions and impaired the responsiveness of ischemic myocardium to proangiogenic agents. In addition, the rarefaction of capillaries also contributes to the overexpression of angiotensin II (Ang2),^[27] which in turn exacerbates microvessel rarefaction and destabilization by disrupting the Ang1/Tie2 interaction (which results in a quiescent and mature state of vessels).^[28] In addition to promoting microvascular rarefaction, the increased expression of Ang2 also accelerates organ fibrosis,^[29] which can further worsen organ function. This evidence indicates that microvascular rarefaction induced by hyperglycemia is able to trigger a series of deleterious effects by both reducing nutrient supply and exacerbating inappropriate endocrine responses,

and antagonizing microvascular rarefaction could be an important therapeutic target for treating DM.

Various studies have provided evidence that vascular endothelial cell apoptosis induced by hyperglycemia is associated with microvascular rarefaction. Si *et al*^[30] illustrated that protein O-GlcNAcylation was increased under diabetic conditions, which subsequently enhanced endothelial cell apoptosis and gave rise to coronary microvascular disease. In addition, specific deletion of calpain in endothelial cells could convert hyperglycemia-induced microcirculation dysfunction by alleviating cell apoptosis.^[31] The above results suggest that inhibition of apoptosis in endothelial cells is a promising way to treat DM-relevant microvascular rarefaction.

Hyperglycemia is associated with remodeling of the ECM and alteration of the integrin expression profile in DM patients and diabetic animal models.^[32,33] The ECM is a major ligand for integrins, and ECM-integrin interactions have been demonstrated to play a critical role in modulating the insulin response.^[34] Previous research indicated that diabetes-induced fibronectin retention is an important cause of end-stage diabetic renal disease, and reducing fibronectin expression significantly improved diabetic renal fibrosis.^[11] In the current research, we confirmed that high glucose promotes fibronectin expression in HUVECs and further demonstrated that the deletion of fibronectin markedly attenuated high glucose-induced HUVEC apoptosis, whereas the addition of fibronectin aggravated apoptosis in HUVECs. Our research indicated that high glucose-induced fibronectin overexpression was detrimental to cell viability. On the other hand, integrins are a cluster of membrane receptors that has been proven to be upregulated by diabetes and associated with the progression of capillary rarefaction and insulin resistance.^[33] The integrin $\alpha 2$ subunit is highly expressed after stimulation with high glucose, and Kang *et al*^[35] reported that the deletion of the integrin $\alpha 2$ subunit significantly increased insulin sensitivity and vascularity in diabetic mice. In our research, we discovered that high glucose promoted the expression of the *ITGB5* in vascular endothelial cells. We further demonstrated that knockdown of the *ITGB5* attenuated high glucose-induced endothelial cell apoptosis by modulating FoxO1-mediated autophagy. Our research expanded the understanding of the role played by integrins in diabetes.

Autophagy is a catabolic process that plays a critical role in maintaining cell viability under stress conditions. Macroautophagy is a type of autophagy that is characterized by the formation of a double-membrane structure (called an autophagosome) that is used to package deleterious molecules or damaged organelles and send them to lysosomes for degradation. However, overactive autophagy has been proven to be detrimental to cellular homeostasis and aggravate cell apoptosis.^[36] It has been demonstrated that high glucose conditions can induce oxidative stress in cells, which subsequently causes damage to organelles (such as mitochondria) and molecules and elevates autophagic flux.^[37] Although it is

reasonable to regard autophagy as a protective mechanism that prevents high glucose-induced damage, the role played by autophagy in diabetic conditions seems to be more paradoxical. While some studies have indicated that autophagy is a protective process for cells in hyperglycemia,^[38] others reported that alleviating autophagy also produced beneficial effects on cells under the stimulation of high glucose.^[39] The controversial result might be attributed to the different cell types that were investigated by researchers.^[40] In this study, we examined the effects of autophagy elicited by high glucose and fibronectin on vascular endothelial cells. We revealed that both high glucose and fibronectin can significantly promote autophagy flux and apoptosis in HUVECs. In addition, through immunoblotting analysis, we found that the expression of beclin1 was elevated, which was proven to be an initiator of the autophagy process by previous studies.^[41] After knocking down the expression of *beclin1*, apoptosis induced by high glucose and fibronectin was markedly attenuated. These results indicated that in vascular endothelial cells, autophagy acted as a promoter of high glucose-induced apoptosis. FoxO1 is a ubiquitously expressed transcription factor in mammalian cells and has been shown to be an important regulator of the autophagy process.^[42] FoxO1-mediated autophagy was proven to be associated with detrimental effects elicited by hyperglycemia.^[43] Prior research reported that FoxO1 correlated with the apoptosis induced by advanced glycation end products (AGEs). Zhang *et al*^[23] demonstrated that the knockdown of *FoxO1* in endothelial cells alleviated AGE-induced apoptosis by reducing autophagy activity and repairing autophagy flux. In our research, we confirmed that FoxO1 is an indispensable downstream target through which the *ITGB5* regulates autophagy-related apoptosis. The deletion of *ITGB5* markedly decreased the expression of FoxO1 and attenuated its nuclear translocation, which subsequently induced a reduction in autophagy activity. In contrast, the overexpression of FoxO1 significantly diminished this protective effect.

This study was mainly based on animal experiments and cell experiments. The results of the study highlighted the need for future research to use a more representative sample in human. Our research provided the evidence that the *ITGB5* was upregulated after high glucose stimulation and strongly promoted apoptosis by elevating autophagy activity. In addition to the antiapoptotic effect, RNA-seq analysis also indicated that the deletion of *ITGB5* could impact the AGE-RAGE pathway, which suggested that the knockdown of *ITGB5* might exert profound anti-inflammatory effects in inhibiting DM complications. Therefore, more efforts should be made to fully understand *ITGB5* in the future. The current study revealed a new mechanism by which the *ITGB5* regulates diabetes-induced vascular endothelial cell apoptosis, which suggested *ITGB5* as a potential target in treating diabetic cardiovascular complications.

Conflicts of interest

None.

References

- Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. Microvascular complications of type 2 diabetes mellitus. *Curr Vasc Pharmacol* 2020;18:117–124. doi: 10.2174/1570161117666190502103733.
- Yan B, Yao J, Liu JY, Li XM, Wang XQ, Li YJ, *et al*. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. *Circ Res* 2015;116:1143–1156. doi: 10.1161/circresaha.116.305510.
- Hayden MR, Sowers JR, Tyagi SC. The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: The matrix preloaded. *Cardiovasc Diabetol* 2005;4:9. doi: 10.1186/1475-2840-4-9.
- Bianchi E, Ripandelli G, Taurone S, Feher J, Plateroti R, Kovacs I, *et al*. Age and diabetes related changes of the retinal capillaries: An ultrastructural and immunohistochemical study. *Int J Immunopathol Pharmacol* 2016;29:40–53. doi: 10.1177/0394632015615592.
- Roy S, Ha J, Trudeau K, Beglova E. Vascular basement membrane thickening in diabetic retinopathy. *Curr Eye Res* 2010;35:1045–1056. doi: 10.3109/02713683.2010.514659.
- Sullivan WJ, Mullen PJ, Schmid EW, Flores A, Momcilovic M, Sharpley MS, *et al*. Extracellular matrix remodeling regulates glucose metabolism through TXNIP destabilization. *Cell* 2018;175:117–132.e21. doi: 10.1016/j.cell.2018.08.017.
- Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. *Cold Spring Harb Perspect Biol* 2011;3:a005058. doi: 10.1101/cshperspect.a005058.
- Peters JH, Hynes RO. Fibronectin isoform distribution in the mouse. I. The alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the developing mouse embryo. *Cell Adhes Commun* 1996;4:103–125. doi: 10.3109/15419069609010766.
- Hynes RO. Cell-matrix adhesion in vascular development. *J Thromb Haemost* 2007;5(Suppl 1):32–40. doi: 10.1111/j.1538-7836.2007.02569.x.
- Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. *Annu Rev Cell Dev Biol* 2010;26:397–419. doi: 10.1146/annurev-cellbio-100109-104020.
- Zheng Z, Ma T, Lian X, Gao J, Wang W, Weng W, *et al*. Clopidogrel reduces fibronectin accumulation and improves diabetes-induced renal fibrosis. *Int J Biol Sci* 2019;15:239–252. doi: 10.7150/ijbs.29063.
- Kechagia JZ, Ivaska J, Roca-Cusachs P. Integrins as biomechanical sensors of the microenvironment. *Nat Rev Mol Cell Biol* 2019;20:457–473. doi: 10.1038/s41580-019-0134-2.
- Roth T, Podestá F, Stepp MA, Boeri D, Lorenzi M. Integrin overexpression induced by high glucose and by human diabetes: Potential pathway to cell dysfunction in diabetic microangiopathy. *Proc Natl Acad Sci U S A* 1993;90:9640–9644. doi: 10.1073/pnas.90.20.9640.
- Su G, Hodnett M, Wu N, Atakilit A, Kosinski C, Godzich M, *et al*. Integrin α v β 5 regulates lung vascular permeability and pulmonary endothelial barrier function. *Am J Respir Cell Mol Biol* 2007;36:377–386. doi: 10.1165/rcmb.2006-0238OC.
- Pasqualini R, Bodorova J, Ye S, Hemler ME. A study of the structure, function and distribution of β 5 integrins using novel anti- β 5 monoclonal antibodies. *J Cell Sci* 1993;105(Pt 1):101–111. doi: 10.1242/jcs.105.1.101.
- Chen J, Maeda T, Sekiguchi K, Sheppard D. Distinct structural requirements for interaction of the integrins α 5 β 1, α v β 5, and α v β 6 with the central cell binding domain in fibronectin. *Cell Adhes Commun* 1996;4:237–250. doi: 10.3109/15419069609010769.
- Jin DK, Fish AJ, Wayner EA, Mauer M, Setty S, Tsilibary E, *et al*. Distribution of integrin subunits in human diabetic kidneys. *J Am Soc Nephrol* 1996;7:2636–2645. doi: 10.1681/asn.V7122636.
- Chatterjee I, Baruah J, Lurie EE, Wary KK. Endothelial lipid phosphate phosphatase-3 deficiency that disrupts the endothelial barrier function is a modifier of cardiovascular development. *Cardiovasc Res* 2016;111:105–118. doi: 10.1093/cvr/cvw090.
- Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identifica-

- tion by morphologic and immunologic criteria. *J Clin Invest* 1973;52:2745–2756. doi: 10.1172/jci107470.
20. Lagache T, Sauvonnnet N, Danglot L, Olivo-Marin JC. Statistical analysis of molecule colocalization in bioimaging. *Cytometry A* 2015;87:568–579. doi: 10.1002/cyto.a.22629.
 21. Duan L, Zhang XD, Miao WY, Sun YJ, Xiong G, Wu Q, *et al.* PDGFR β cells rapidly relay inflammatory signal from the circulatory system to neurons via chemokine CCL2. *Neuron* 2018;100:183–200.e8. doi: 10.1016/j.neuron.2018.08.030.
 22. Anders S, Huber W. Differential expression analysis for sequence count data. *Genome Biol* 2010;11:R106. doi: 10.1186/gb-2010-11-10-r106.
 23. Zhang H, Ge S, He K, Zhao X, Wu Y, Shao Y, *et al.* FoxO1 inhibits autophagosome-lysosome fusion leading to endothelial autophagic-apoptosis in diabetes. *Cardiovasc Res* 2019;115:2008–2020. doi: 10.1093/cvr/cvz014.
 24. Forbes JM, Cooper ME. Mechanisms of diabetic complications. *Physiol Rev* 2013;93:137–188. doi: 10.1152/physrev.00045.2011.
 25. Li W, Yanoff M, Liu X, Ye X. Retinal capillary pericyte apoptosis in early human diabetic retinopathy. *Chin Med J* 1997;110:659–663.
 26. Hinkel R, Howe A, Renner S, Ng J, Lee S, Klett K, *et al.* Diabetes mellitus-induced microvascular destabilization in the myocardium. *J Am Coll Cardiol* 2017;69:131–143. doi: 10.1016/j.jacc.2016.10.058.
 27. Hammes HP, Lin J, Wagner P, Feng Y, Vom Hagen F, Krzizok T, *et al.* Angiopoietin-2 causes pericyte dropout in the normal retina: Evidence for involvement in diabetic retinopathy. *Diabetes* 2004;53:1104–1110. doi: 10.2337/diabetes.53.4.1104.
 28. Tuo QH, Zeng H, Stinnett A, Yu H, Aschner JL, Liao DF, *et al.* Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. *Am J Physiol Heart Circ Physiol* 2008;294:H2547–H2557. doi: 10.1152/ajpheart.01250.2007.
 29. Gonzalez-Quesada C, Cavalera M, Biernacka A, Kong P, Lee DW, Saxena A, *et al.* Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. *Circ Res* 2013;113:1331–1344. doi: 10.1161/circresaha.113.302593.
 30. Si R, Zhang Q, Tsuji-Hosokawa A, Watanabe M, Willson C, Lai N, *et al.* Overexpression of p53 due to excess protein O-GlcNAcylation is associated with coronary microvascular disease in type 2 diabetes. *Cardiovasc Res* 2020;116:1186–1198. doi: 10.1093/cvr/cvz216.
 31. Teng X, Ji C, Zhong H, Zheng D, Ni R, Hill DJ, *et al.* Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. *Diabetologia* 2019;62:860–872. doi: 10.1007/s00125-019-4828-y.
 32. Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. *Diabetes* 2011;60:2354–2369. doi: 10.2337/db10-1181.
 33. Wasserman DH, Wang TJ, Brown NJ. The vasculature in prediabetes. *Circ Res* 2018;122:1135–1150. doi: 10.1161/circresaha.118.311912.
 34. Williams AS, Kang L, Wasserman DH. The extracellular matrix and insulin resistance. *Trends Endocrinol Metab* 2015;26:357–366. doi: 10.1016/j.tem.2015.05.006.
 35. Kang L, Ayala JE, Lee-Young RS, Zhang Z, James FD, Neuffer PD, *et al.* Diet-induced muscle insulin resistance is associated with extracellular matrix remodeling and interaction with integrin α 2 β 1 in mice. *Diabetes* 2011;60:416–426. doi: 10.2337/db10-1116.
 36. Denton D, Nicolson S, Kumar S. Cell death by autophagy: Facts and apparent artefacts. *Cell Death Differ* 2012;19:87–95. doi: 10.1038/cdd.2011.146.
 37. Sarparanta J, García-Macia M, Singh R. Autophagy and mitochondria in obesity and type 2 diabetes. *Curr Diabetes Rev* 2017;13:352–369. doi: 10.2174/1573399812666160217122530.
 38. Jin Y, Liu S, Ma Q, Xiao D, Chen L. Berberine enhances the AMPK activation and autophagy and mitigates high glucose-induced apoptosis of mouse podocytes. *Eur J Pharmacol* 2017;794:106–114. doi: 10.1016/j.ejphar.2016.11.037.
 39. Niu C, Chen Z, Kim KT, Sun J, Xue M, Chen G, *et al.* Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway. *Autophagy* 2019;15:843–870. doi: 10.1080/15548627.2019.1569913.
 40. Yao D, Gang Yi Y, QiNan W. Autophagic dysfunction of β cell dysfunction in type 2 diabetes, a double-edged sword. *Genes Dis* 2021;8:438–447. doi: 10.1016/j.gendis.2020.03.003.
 41. Maejima Y, Isobe M, Sadoshima J. Regulation of autophagy by Beclin 1 in the heart. *J Mol Cell Cardiol* 2016;95:19–25. doi: 10.1016/j.yjmcc.2015.10.032.
 42. Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, *et al.* Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. *Nat Cell Biol* 2010;12:665–675. doi: 10.1038/ncb2069.
 43. Jiang Y, Luo W, Wang B, Yi Z, Gong P, Xiong Y. $1\alpha, 25$ -Dihydroxyvitamin D₃ ameliorates diabetes-induced bone loss by attenuating FoxO1-mediated autophagy. *J Biol Chem* 2021;296:100287. doi: 10.1016/j.jbc.2021.100287.

How to cite this article: Lin XZ, Huang SZ, Gao SD, Liu JX, Tang J, Yu MY. Integrin β 5 subunit regulates hyperglycemia-induced vascular endothelial cell apoptosis through FoxO1-mediated macroautophagy. *Chin Med J* 2024;137:565–576. doi: 10.1097/CM9.0000000000002769